MRI scanning News
-
Showcase
Corify Care participated in the CEI Satellite Meeting CinC 2020: Challenges in the Daily Application of ECGI
Last 18th of September, Corify Care CEO and co-founder, Dr. Andreu Climent participated in the CEI Satellite Meeting CinC 2020: ECGI Past, Present, and Future: from Engineering to Clinical Application organised by the Consortium for ECG Imaging. The objective was to discuss engineering hurdles for ECGI being incorporated into clinical practice and are partnering with industry leaders to ...
-
Announcement – Total Shoulder Arthroplasty (TSA) Planning Through MRI Scan
RSIP Vision, an experienced leader in driving innovation for medical imaging through advanced AI and computer vision solutions, today announces a new tool for Total Shoulder Arthroplasty (TSA) planning. This tool performs segmentation of the shoulder bones from shoulder MRI scan, which is usually performed in shoulder healthcare. The segmentation output undergoes super-resolution enhancement to ...
By RSIP Vision
-
Assessing CDM measures in grey matter micro structure in AD Patients for Takeda Pharmaceuticals
Oxford Brain Diagnostics has started a project for Takeda Pharmaceuticals. The project is testing Cortical Disarray Measurement (CDM®) technology as a neurodegeneration biomarker with a view to using it in future clinical trials. Dr Steven Chance, CEO, said ‘we are very excited to be engaged with Takeda on this project using our CDM method on diffusion MRI scans. Alzheimer’s ...
-
Announcement – New AI Tool for Prostate MRI Analysis to Support PI-RADS Scoring
Innovative technology performs automatic segmentation and lesion detection in prostate MRI scans to assist in PI-RADS scoring for prostate cancer management. RSIP Vision, an experienced leader in driving innovation for medical imaging through advanced Artificial Intelligence (AI) and computer vision solutions, today announces a new tool for prostate MRI analysis. The tool performs segmentation ...
By RSIP Vision
-
Global Regulatory Organization Certifies Optimizer Smart Device as Compliant for Whole-Body MRI Scans in the EU
Impulse Dynamics, an international medical device company dedicated to improving the lives of people with heart failure (HF), today announced that DEKRA Certification B.V. (DEKRA), a global regulatory organization, approved labeling for the Optimizer® Smart device for conditional full-body MRI scans utilizing 1.5 Tesla scanners in the EU. DEKRA, known for ensuring the safe use of ...
-
Oxford Brain Diagnostics wins funding from the National Institute for Health Research (NIHR) to test Alzheimer’s diagnostic in NHS
Oxford Brain Diagnostics Ltd, a software company focused on developing diagnostics based on changes in the brain at the cellular level, is delighted to announce that we have been awarded funding by the National Institute for Health Research (NIHR) to assess CDM® as a novel and promising tool to identify and predict disease progression amongst patients presenting with mild cognitive impairment ...
-
Leading US cancer clinic installs first optical communication system for MRI
Optoacoustics announced that The University of Texas M. D. Anderson Cancer Center (MDACC) has installed the leading-edge IMROC™ communication system for use in its clinical Interventional MRI Suite, one of the most advanced facilities of its type in the world.Optoacoustics' Interventional MR Optical Communication System (IMROC) is the only system that enables doctors in interventional MRI (iMRI) ...
-
Qynapse to Sponsor and Present New Data on QyPredict at Clinical Trials on Alzheimer’s Disease Conference (CTAD 2021)
BOSTON, MA, November 4, 2021, PRNewswire – Qynapse Inc., a medical technology company commercializing an AI-powered neuroimaging software platform for central nervous system (CNS) disorders, is pleased to sponsor the 14th Clinical Trials on Alzheimer’s Disease conference (CTAD) to be held from November 9-12, 2021, in Boston, MA. Qynapse will present new results on Qypredict®, ...
By Qynapse
-
Cost Effectiveness of MRI for Early Detection of Prostate Cancer
Prostate cancer is the second most common and lethal cancer among men in the United States. In 2021, an estimated 250,000 men were diagnosed, with the majority over 65 years old. During the height of the pandemic, diagnosis and screening numbers plummeted, resulting in thousands of missed diagnoses. Lost in the surgical backlog, already delayed diagnoses may be further delayed, potentially ...
-
CVRx Receives MR-Conditional Labeling Approval for its Barostim Heart Failure System
MINNEAPOLIS, MAY 9,2022 - CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), developer of the world's first FDA-approved neuromodulation device to treat the symptoms of heart failure, has received U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR) conditional labeling for its Barostim System. The Barostim System now includes instructions to allow for safe MRI scans of the head and ...
By CVRx
-
Subtle Medical to Become the First Partner Siemens Healthineers Welcomes on Board Their New Open Recon¹ Interface
Subtle Medical, a key provider of artificial intelligence (AI) solutions for medical imaging, and Siemens Healthineers, a leading medical technology company, announced today a partnership to integrate Subtle Medical’s SubtleMR™ image-enhancement software into the MRI machines of Siemens Healthineers. SubtleMR™ will be incorporated into the planned reconstruction pipeline of ...
-
Oxford Brain Diagnostics establishes a research-based clinical MRI study in Japan to investigate how Cortical Disarray Measurement (CDM) analysis may support differential diagnosis and estimate disease severity in Dementia patients
Oxford Brain Diagnostics Ltd, a software company focused on developing diagnostics based on changes in the brain at the cellular level, is delighted to announce that we have established a research collaboration with Principal Investigator Dr Takashi Nakajima, MD, PhD at Niigata Hospital and Dr Kazuo Shigematsu at Minami Kyoto National Hospital. In Japan, clinical MRI scanners are available for ...
-
Axial3D and BIOMODEX Announce Strategic Partnership
Axial3D, an award-winning medical imaging technology company, headquartered in Belfast has announced a partnership with BIOMODEX®, the leader in biorealistic haptic simulators for physician training and rehearsals. The partnership will enable Biomodex to speed the production of 3D-printed brain aneurysm models by reducing the time it takes to transform 2D medical images to 3D visuals. An ...
By Axial3D
-
Qynapse Unveils its New Brand and Latest Developments in Neuroimaging AI Innovation at the 2021 RSNA Meeting in Chicago
BOSTON, MA, November 22, 2021, PRNewswire – Qynapse Inc., a medical technology company commercializing an artificial intelligence (AI)-powered neuroimaging software platform for central nervous system (CNS) disorders, will unveil its new brand and latest AI developments as a key exhibitor in the AI Showcase at the 107th Radiology Society of North America (RSNA) Annual Meeting, from ...
By Qynapse
-
CardioWise Completes Small Business Innovation and Research Grant from the National Science Foundation
CardioWise, Inc. has completed National Science Foundation (NSF) Phase I and IB Small Business Innovation and Research (SBIR) grants that continued the development and commercialization of a non-invasive analysis method for detection of heart disease. The final report submitted to the NSF in December detailed the research and development milestones that were achieved during the 2013 award period ...
-
Oxford Brain Diagnostics awarded FDA Breakthrough Device Designation for technology to predict Alzheimer’s Disease
Oxford Brain Diagnostics Ltd, a spinout from the University of Oxford specialising in the measurement of neurodegeneration in Alzheimer’s disease, today announces that the US Food and Drug Administration (FDA) has awarded Breakthrough Device Designation to its Cortical Disarray Measurement (CDM®) Software Device for evaluating adults at risk of Alzheimer’s disease Oxford Brain ...
-
Nalu Micro-Implantable Pulse Generator Receives Expanded FDA Label for Service Life of 18 Years
Nalu Medical, Inc. (“Nalu”), a California-based company that has successfully miniaturized neurostimulation implants for the treatment of chronic pain via Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS), in July 2020 received clearance from the U.S. Food and Drug Administration (FDA) of an expanded label for its micro-Implantable Pulse Generator (mIPG) to an ...
-
NFL & GE Announce Six Final Winners of $10 Million Head Health Challenge
Innovations are advancing the understanding and diagnosis of mild traumatic brain injury Breakthrough ideas include: point-of-care blood test to rapidly detect the presence of mild and moderate brain trauma; biomarkers that indicate how the brain reacts following a traumatic brain injury (TBI) and a method to identify which brain areas become disconnected after injury GE (NYSE: GE) and the ...
-
Dogs Demonstrate Ability to Detect COVID-19
It is no secret that dogs have long been used for purposes other than companionship. Because of an acute sense of smell, dogs can be trained in medical arenas to detect cancer, diabetes, and other chronic diseases or conditions. You may have also seen the incredible sniffing power of dogs used in missing persons cases, illegal drugs, and hunting applications. Therefore, researchers are now ...
-
Oxford Brain Diagnostics’ grey matter quality measure selected as secondary outcome for Alzheimer’s Phase 2 clinical trial
Approximately 201 patients will be enrolled to study the XPro™ intervention. The objectives of this study are to determine the safety, tolerability, and efficacy of XPro™ in patients with mild AD. Oxford, UK, 29th March 2022. Oxford Brain Diagnostics, a software company focused on developing diagnostics that identify changes in the brain at a cellular level, today announced that ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you